Jefferies lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $53 from $70 and keeps a Buy rating on the shares. The firm’s forecast for CRB-913 peak sales has been lowered to $1.2B from $1.7B, the analyst noted. The CRB-913 obesity study will dose its first patient by the end of March and Corbus is likely to share data from the dose-ranging study in the first half of 2026, Jefferies added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals Reports Q4 2024 Financial Results
- Corbus Pharmaceuticals reports Q4 EPS (78c), consensus ($1.26)
- Elastic, Monster, Caesars, Catalyst, Corbus: Stock Shake-Up!
- Corbus Pharmaceuticals initiated with an Outperform at William Blair
- Corbus Pharmaceuticals: Promising ADC Advancements with CRB-701 and Market Opportunities Amidst Risks